

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

## Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2019.

PART-I													(Rs. In Lakhs)	
Sr. No.	Particulars	Standalone						Consolidated						
		Quarter Ended			Nine Months Ended			Quarter Ended			Nine Months Ended			Year Ended
		31/12/2019 (Un-Audited)	30/09/2019 (Un-Audited)	31/12/2018 (Un-Audited)	31/12/2019 (Un-Audited)	31/12/2018 (Un-Audited)	31/03/2019 (Audited)	31/12/2019 (Un-Audited)	30/09/2019 (Un-Audited)	31/12/2018 (Un-Audited)	31/12/2019 (Un-Audited)	31/12/2018 (Un-Audited)	31/03/2019 (Audited)	
<b>1</b>	<b>Income</b>													
	A) Revenue From Operations	9,563.99	11,059.69	8,100.18	30,082.63	27,558.20	35,304.25	9,852.39	11,268.72	8,443.49	30,802.37	28,686.01	36,618.10	
	B) Other Income	236.62	287.60	53.47	682.17	716.97	657.54	303.47	252.36	37.97	685.27	652.31	565.08	
	<b>Total Income</b>	<b>9,800.61</b>	<b>11,347.29</b>	<b>8,153.65</b>	<b>30,764.80</b>	<b>28,275.17</b>	<b>35,961.79</b>	<b>10,155.86</b>	<b>11,521.08</b>	<b>8,481.46</b>	<b>31,487.64</b>	<b>29,338.32</b>	<b>37,183.18</b>	
<b>2</b>	<b>Expenses</b>													
	A) Cost of Material Consumed	2,772.81	3,025.26	1,466.42	8,151.68	5,983.71	8,083.52	3,471.55	4,934.60	2,445.99	10,604.20	8,664.16	11,319.76	
	B) Purchase of Stock-In-Trade	2,613.51	2,668.80	2,244.76	7,280.35	6,693.75	8,891.00	1,892.05	654.74	1,326.98	4,581.24	3,757.31	5,174.51	
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	(446.88)	21.06	55.26	(315.29)	848.26	733.30	(471.78)	(35.11)	(106.99)	(405.42)	1,002.64	1,045.82	
	D) Employee Benefits Expenses	1,342.06	1,458.43	1,385.39	4,240.18	3,837.98	4,840.06	1,424.96	1,541.23	1,469.90	4,490.66	4,095.00	5,190.18	
	E) Finance Costs	45.98	57.18	77.40	167.56	305.18	384.35	134.74	58.05	70.87	257.38	321.07	399.71	
	F) Depreciation and Amortisation Expense	141.24	129.92	148.92	410.65	370.06	491.91	188.27	177.12	193.92	550.06	502.77	667.90	
	G) Other Expenses	2,127.12	1,624.93	1,648.20	5,563.22	5,118.16	6,723.42	2,216.53	1,705.16	1,946.64	5,839.73	5,567.91	7,165.85	
	<b>Total Expenses</b>	<b>8,595.84</b>	<b>8,985.59</b>	<b>7,026.35</b>	<b>25,498.36</b>	<b>23,157.10</b>	<b>30,147.56</b>	<b>8,856.32</b>	<b>9,035.78</b>	<b>7,347.31</b>	<b>25,917.85</b>	<b>23,910.86</b>	<b>30,963.73</b>	
<b>3</b>	<b>Profit / (Loss) Before Exceptional Items &amp; Tax (1-2)</b>	<b>1,204.77</b>	<b>2,361.70</b>	<b>1,127.30</b>	<b>5,266.44</b>	<b>5,118.07</b>	<b>5,814.23</b>	<b>1,299.54</b>	<b>2,485.30</b>	<b>1,134.15</b>	<b>5,569.79</b>	<b>5,427.46</b>	<b>6,219.45</b>	
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil	
<b>5</b>	<b>Profit / (Loss) after Exceptional items but Before Tax (3-4)</b>	<b>1,204.77</b>	<b>2,361.70</b>	<b>1,127.30</b>	<b>5,266.44</b>	<b>5,118.07</b>	<b>5,814.23</b>	<b>1,299.54</b>	<b>2,485.30</b>	<b>1,134.15</b>	<b>5,569.79</b>	<b>5,427.46</b>	<b>6,219.45</b>	
	Tax Expense													
	A) Current Tax (Net)	210.59	547.78	224.80	1,269.70	1,353.81	1,429.00	248.18	589.61	228.55	1,353.38	1,487.61	1,508.10	
	B) Deferred Tax (Net)	(23.57)	15.09	(42.73)	(36.30)	(181.96)	(278.49)	(40.78)	2.90	(8.67)	(36.17)	(82.69)	(162.53)	
<b>7</b>	<b>Profit / (Loss) For The Period (5-6)</b>	<b>1,017.75</b>	<b>1,798.83</b>	<b>945.24</b>	<b>4,033.03</b>	<b>3,946.22</b>	<b>4,663.72</b>	<b>1,092.14</b>	<b>1,892.79</b>	<b>914.27</b>	<b>4,252.58</b>	<b>4,022.54</b>	<b>4,873.88</b>	
	Attributable to:													
	Non-Controlling Interest	Nil	Nil	Nil	Nil	Nil	Nil	1.04	1.34	(0.41)	3.10	1.08	2.86	
	<b>Owners of the Company</b>	<b>1,017.75</b>	<b>1,798.83</b>	<b>945.24</b>	<b>4,033.03</b>	<b>3,946.22</b>	<b>4,663.72</b>	<b>1,091.09</b>	<b>1,891.45</b>	<b>914.68</b>	<b>4,249.48</b>	<b>4,021.46</b>	<b>4,871.02</b>	
9	Other Comprehensive Income (Net Of Tax)	1.08	1.09	2.30	3.25	6.90	4.34	0.83	0.82	2.48	2.48	7.41	3.31	
<b>10</b>	<b>Total Comprehensive Income</b>	<b>1,018.84</b>	<b>1,799.91</b>	<b>947.54</b>	<b>4,036.29</b>	<b>3,953.12</b>	<b>4,668.06</b>	<b>1,091.92</b>	<b>1,892.27</b>	<b>917.16</b>	<b>4,251.96</b>	<b>4,028.87</b>	<b>4,874.33</b>	
11	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	
12	Other Equity						24,260.41						24,934.45	
<b>13</b>	<b>Earnings Per Share (of Rs. 10/- Each) (Not Annualised)</b>													
	(a) Basic	5.09	8.99	4.73	20.17	19.73	23.32	5.46	9.46	4.57	21.25	20.11	24.36	
	(b) Diluted	5.09	8.99	4.73	20.17	19.73	23.32	5.46	9.46	4.57	21.25	20.11	24.36	

NOTES:												
1	The Financial Results of the Company for the Quarter and Nine Months Ended December 31, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on February 13, 2020. The Statutory Auditors of the Company have carried out Limited Review of these Results and the Results are being Published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.											
2	These Financial Results have been prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter.											
3	The Board of Directors in its meeting dated December 07, 2019 approved the scheme of amalgamation of Lincoln Parenteral Limited (Transferor Company) and Lincoln Pharmaceuticals Limited (Transferee Company) under Section 230 to 232 of the Companies Act, 2013. The scheme is subject to the approval of NCLT. The appointed date of the scheme of amalgamation is April 01, 2019.											
4	Effective April 1, 2019, the Company has adopted Ind AS 116 to all contracts existing on April 1, 2019. The effect of adoption is not material on profit and earning per share for the Quarter and Nine Months Ended December 31, 2019.											
5	Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.											
6	Comparative figures have been rearranged/regrouped wherever necessary.											
7	Consolidated Results includes results of its subsidiaries.											

FOR LINCOLN PHARMACEUTICALS LIMITED

PLACE: AHMEDABAD  
DATE: FEBRUARY 13, 2020

Sd/-  
MAHENDRA G. PATEL  
MANAGING DIRECTOR  
DIN: 00104706